1. Secondary resistance to the PI3K inhibitor copanlisib in marginal zone lymphoma
- Author
-
Alberto J. Arribas, Francesco Bertoni, Filippo Spriano, Giulio Sartori, Z. Emanuele, R. Bordone-Pittau, Sara Napoli, Davide Rossi, Anastasios Stathis, Andrea Rinaldi, Marilia Barreca, T. Chiara, Eugenio Gaudio, Luciano Cascione, Georg Stussi, and A. Arribas, S. Napoli, L. Cascione, E. Gaudio, R. Bordone-Pittau, M. Barreca, G. Sartori, T. Chiara, F. Spriano, A. Rinaldi, A. Stathis, G. Stussi, D. Rossi, Z. Emanuele, F. Bertoni
- Subjects
Cancer Research ,chemistry.chemical_compound ,Oncology ,chemistry ,Resistance (ecology) ,Marginal zone lymphoma ,Cancer research ,lymphoma ,PI3K inhibitor ,Biology ,PI3K/AKT/mTOR pathway ,Copanlisib - Abstract
PI3K kinase has a prominent role in the B-cell receptor signaling. Copanlisib, a pan-PI3K inhibitor with predominant selectivity to PI3Kα and PI3Kδ, is Food and Drug Administration (FDA) approved for the treatment of patients with relapsed or refractory follicular lymphoma, and it is currently under clinical development in other indolent lymphomas including marginal zone lymphoma (MZL). However some patients might eventually relapse because of acquired resistance and so a better understanding of resistance mechanisms is needed. Thus we generated MZL cell lines resistant to copanlisib which could help to design improved therapies
- Published
- 2020